Autopsy report · NCT04521296

Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo

“Changes in drug development plans”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year 6 months before it stopped.
• 432 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

Daewoong Pharmaceutical Co. LTD.

Sponsor type

Industry

Conditions

Mild to Moderate COVID-19

Interventions

Part 1; Part 2

Participants

432

Sites

1

Countries

South Korea

Trials that died the same way

• Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
  “Change in clinical plan and drug supply” (74% match in meaning)
• Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer
  “Drug development stopped” (72% match in meaning)
• Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy
  “Stop of drug development” (71% match in meaning)
• Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
  “Change in the clinical development plan” (70% match in meaning)
• Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
  “the change of clinical development plan” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.